BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 3153444)

  • 21. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review.
    Singh S
    Indian J Dermatol Venereol Leprol; 2011; 77(4):456-69. PubMed ID: 21727693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid.
    Cozzani E; Drosera M; Parodi A; Carrozzo M; Gandolfo S; Rebora A
    Acta Derm Venereol; 2004; 84(5):381-4. PubMed ID: 15370705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC; Jiao D
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
    Turner MS; Sutton D; Sauder DN
    J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma exchange therapy].
    Klemm-Mayer H
    Z Hautkr; 1984 Nov; 59(21):1423-5. PubMed ID: 6516508
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasmapheresis therapy of pemphigus.
    Bystryn JC
    Arch Dermatol; 1988 Nov; 124(11):1702-4. PubMed ID: 3178250
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of pemphigus and pemphigoid].
    Schaumburg-Lever G
    Z Hautkr; 1986 Jun; 61(11):811-2. PubMed ID: 3526731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to apheresis: problems of assessment in immune disease.
    Jones JV
    Clin Nephrol; 1986; 26 Suppl 1():S70-5. PubMed ID: 3829471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observations of the immunopathology and therapy of canine pemphigus and pemphigoid.
    Scott DW; Manning TO; Smith CA; Lewis RM
    J Am Vet Med Assoc; 1982 Jan; 180(1):48-52. PubMed ID: 6799473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
    Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
    Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adjuvant therapy of pemphigus. An update.
    Bystryn JC; Steinman NM
    Arch Dermatol; 1996 Feb; 132(2):203-12. PubMed ID: 8629830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemphigus and pemphigoid.
    Matsuoka LY
    Am Fam Physician; 1981 Aug; 24(2):113-5. PubMed ID: 7020393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bullous pemphigoid with pemphigus type antibodies in vivo. 2 cases].
    Bernard P; Catanzano G; Vignaud St Florent JD; Fayol J; Bonnetblanc JM
    Ann Dermatol Venereol; 1986; 113(8):671-6. PubMed ID: 3541760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
    Budimir J; Mihić LL; Situm M; Bulat V; Persić S; Tomljanović-Veselski M
    Acta Clin Croat; 2008 Mar; 47(1):13-8. PubMed ID: 18714642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of pemphigus desmoglein 1 and desmoglein 3 autoantibodies and pemphigoid BP180 autoantibodies in saliva and comparison with serum values.
    Andreadis D; Lorenzini G; Drakoulakos D; Belazi M; Mihailidou E; Velkos G; Mourellou-Tsatsou O; Antoniades D
    Eur J Oral Sci; 2006 Oct; 114(5):374-80. PubMed ID: 17026501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic use of plasmapheresis in a patient with bullous pemphigoid].
    Bandemir W; Krëger E
    Vestn Dermatol Venerol; 1989; (2):10-3. PubMed ID: 2658406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bullous pemphigoid and pemphigus vulgaris.
    Patel HP; Anhalt GJ; Diaz LA
    Ann Allergy; 1983 Mar; 50(3):144-50. PubMed ID: 6338766
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.
    Gürcan HM; Ahmed AR
    Am J Clin Dermatol; 2009; 10(6):383-96. PubMed ID: 19824739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.